Eli Lilly Expands Biotech Portfolio with Trio of Vaccine Acquisitions
Strategic Pivot in Pharmaceutical Development Eli Lilly and Company, the global pharmaceutical leader currently dominating the market with its high-demand weight-loss therapies, announced this week a definitive agreement to acquire three specialized vaccine developers. This strategic expansion marks a significant pivot for the Indianapolis-based firm, which is moving to diversify its pipeline by re-engaging with…